TABLE 1

Patient Characteristics, Tumoral Tracer Uptake, and Proliferation Fraction (Ki-67 Index)

Patient no.	Age (y)	Sex	Pathology finding	Tumor grade	Pretreatment	FLT			FDG			Surgery after PET	Ki-67 index (%)
Patient no.	Age (y)	Sex	Pathology finding	Tumor grade	Pretreatment							Surgery after PET	Ki-67 index (%)	SUV_max	T/N ratio	SUV_max	T/N ratio
1	29	F	Glioblastoma	IV	Gamma knife/RT/chemo	0.97	3.64	4.88	0.52	Yes	10
2	65	M	Glioblastoma	IV	Surgery/RT/chemo	1.69	4.88	6.24	1.04	Yes	5
3	63	M	Glioblastoma	IV	Surgery/RT/chemo	1.38	5.12	6.87	2.31	Yes	25
4	56	M	Glioblastoma	IV	Biopsy only	1.23	3.55	2.97	1.02	Yes	10
5	66	M	Glioblastoma	IV	Subtotal resection	2.62	3.93	7.48	2.05	Yes	25
6	52	M	Glioblastoma	IV	Surgery/RT/chemo	2.16	4.68	3.36	1.66	Yes	40
7	65	M	Glioblastoma	IV	Biopsy only	1.15	4.51	7.37	1.40	Yes	40
8	73	M	Glioblastoma	IV	Biopsy/RT	0.88	3.33	2.54	0.80	Yes	2
9	26	M	Anaplastic mixed	III	Biopsy/RT	0.70	3.00	1.75	0.52	Yes	4
10	31	M	Glioblastoma	IV	Biopsy only	3.62	5.81	6.01	2.46	Yes	75
11	40	M	Glioblastoma	IV	Biopsy only	0.40	1.85	4.44	1.03	No	—
12	27	F	Anaplastic mixed	III	Surgery/RT/chemo	0.83	2.70	16.0	2.89	No	—
13	58	F	Glioblastoma	IV	Surgery/RT/chemo	1.02	3.48	5.95	1.45	No	—
14	37	M	Glioblastoma	IV	Surgery/RT/chemo	1.43	3.62	4.90	0.90	No	—
15	60	F	Glioblastoma	IV	Surgery/RT/chemo	1.14	3.28	3.20	0.76	No	—
16	59	M	Glioblastoma	IV	Surgery/RT/chemo	1.07	2.64	7.47	1.18	No	—
17	45	M	Anaplastic oligodendroglioma	III	Surgery/ BCNU wafer*	0.95	3.10	3.25	0.94	No	—
18	33	F	Astrocytoma	II	Surgery	0.30	0.77	2.20	0.61	Yes	2
19	59	F	Oligodendroglioma	II	Surgery	0.27	1.02	4.47	0.81	Yes	2
20	31	M	Oligodendroglioma	II	Biopsy only	0.42	1.03	2.77	1.04	Yes	3
21	34	F	Mixed glioma	II	Biopsy only	0.25	1.10	3.20	0.88	No	—
22	51	M	Glioblastoma^†	IV	Surgery/RT/chemo	0.35	1.07	2.41	0.47	No	—
23	44	M	Anaplastic mixed^†	III	Surgery/RT/chemo	0.27	1.06	1.36	1.14	No	—
24	65	M	Anaplastic oligodendroglioma^†	III	Surgery/RT/chemo	0.22	0.93	2.16	0.41	No	—
25	24	F	Anaplastic oligodendroglioma	III	Biopsy only	1.27	1.95	3.43	0.83	Yes	10

↵* Patient had 1,3-bis-2-chloroethyl-1-nitrosourea (BCNU) wafer implanted at resection site during resective surgery.
↵^† Three patients had previously treated gliomas and had been off therapy and stable without clinical or MRI evidence of recurrent disease for >3 y.
SUV_max = maximum-pixel standardized uptake value; T/N ratio = ratio of mean uptake of voxels with top 20% SUVs to mean values of contralateral normal brain; RT = radiation therapy; chemo = chemotherapy.